The identification of radiation sensitive or resistant individuals within an apparently normal population is of potential importance for radiotherapy, radiological protection and detection of genetic susceptibility to cancer. It has long been recognised that tumours of different histological types differ in radioresponsiveness. More recently, it has become clear that there are differences in radiosensitivity both between and within tumour classes. These are important because small differences in radiosensitivity represent potentially large differences in tumour curability after the large cumulative doses delivered in radiotherapy. There is also a generally held opinion that not only tumours, but apparently normal individuals differ in their intrinsic radiosensitivity, as evidenced by a small number of patients suffering severe normal tissue damage following radiotherapy.
Over the past decade, more than 2,000 people have been tested for their intrinsic cellular radiosensitivity. These measurements have been carried out using a variety of endpoints (cell killing, cell growth delay, DNA damage/repair, chromosome damage) and cell types (tumour, lymphocyte, fibroblast) at a number of different centres around the world. Many of those involved were invited to the Paterson Institute to discuss whether there is a future for radiosensitivity test- ing.
Tumour cells
There are two large studies measuring the radiosensitivity of human tumours by determining surviving fraction at 2 Gy (SF2). W. Brock (Houston) presented data obtained using the cell adhesive matrix assay (CAM) on 140 head and neck cancers. All the patients had been treated by surgical resection followed by post-operative radiotherapy. The average SF2 value for patients with recurrence was higher but not significantly different from the average SF2 value for those without. However for oral cavity tumours there was a significant difference.
The radiosensitivity of cervical carcinoma assessed using the Courtenay-Mills clonogenic assay was presented by S. There is interest in the use of short-term assays which, although like the CAM assay these may be complicated by the inclusion of normal cells, might produce rankings of values similar to those obtainable using clonogenic assays. One advantage of the MTT assay is the poor ability shown by stromal cells to convert MTT (P. Twentyman, Cambridge) . A disadvantage is that sufficient time must be allowed for untreated cells to undergo four to five doublings (around 2 weeks for primary tumour specimens) which may require regular cell density determinations on parallel cultures. Work of J. Ramsey (Cambridge) was described on early passage lines established from grade III and IV astrocytomas. The most sensitive third (n = 7) showed a statistically significant difference in median survival measured in months when compared with the most radioresistant third (n = 7). Equivalent, although not statistically significant, results were obtained with a clonogenic assay. It should be noted that the MTT assay has not detected the radiosensitivity of ataxia-telangiectase (A-T) lymphoblastoid lines or of lymphoblastoid lines where sensitivity has been demonstrated using either a clonogenic or grow-back assay (N. Gentner, Chalk River).
Quantification of micronuclei (MN) represents an easy and rapid test (3-4 days) which may have use as a predictive assay. The frequency of micronucleated cells in untreated tumours varies within and between tumour classes (C. Streffer, Essen). Local recurrences of rectal carcinomas have been shown to occur with a high probability in tumours with low numbers of MN 
Mechanisms
There was some discussion of possible mechanisms underlying differences in radiosensitivity between cells. G. Steel (Sutton) described the two components of ionising radiation induced cell kill as a linear non-recoverable and a second recoverable component. Work in his Department has shown that both recoverable and non-recoverable damage increase with increasing radiosensitivity i.e. that radiosensitive human tumour cell lines are not recovery deficient. In contrast, these studies confirm the recovery deficiency of A-T fibroblasts. Differences between tumour lines are related to the steepness of the linear component of cell kill and the obvious question of interest is, what is the nature of this component? It could perhaps be related to the production by ion clusters of locally multiply-damaged sites in DNA, or to the presence of hypersensitive regions of the genome. Although the component is described in G. Steel's model as non-recoverable, it should be noted that the component is modifiable by repair inhibitors.
A technique for studying repair and misrepair at specific sites in DNA was described (J. Thacker, Chilton) which has shown increased misrepair in A-T cell lines. In addition to the human genetic disorders, about eight genes controlling radiosensitivity have been identified in cultured mammalian cells. Around 100 yeast mutants sensitive to DNA-damaging agents are known, and there is good homology between yeast and human repair gene products. If there are about 100 genes involved in radiosensitivity in human cells, the frequency of carriers of recessive mutant genes in an apparently normal population would be as high as one in five. Several human repair genes have recently been cloned, and the availability of probes to the genes and gene products offers the prospect of a novel, direct, method for predicting radiosensivity.
Clinical relevance
Parameters which are established as important in the radiation response of human tumours include: histological type, size, grade, clinical presentation and site; radiation dose level and distribution across tumour. Variation in these parameters results in heterogeneity in response to radiotherapy (H. Suit, Boston). Planning a clinical evaluation of a response predictor would accordingly need to be based upon a stratum of patients which is homogeneous with respect to these parameters. Heterogeneity of response is measured by the slope of the dose response curve ('yi). Calculations were presented which showed that the Tm values would be :8, 2 and I for CV's of 1, 13 and ;30%. Therefore the uncertainties associated with the determination of SF2 values (CV ;20% for multiple samples from one tumour) were suggested to be too large for SF2 values to be predictive for 'homogeneous' populations of tumours.
I. Turesson (Gothenberg) discussed evidence for a genetic influence on the variability of response of normal tissues using the clinical work in patients with carcinoma of the breast undertaken at that centre since 1972. The endpoint was the appearance of late skin damage in anterior chest wall. Variations in response have been quantified and a multifactorial analysis carried out of possible factors contributing towards these differences. 
General discussion
In the final summary, J. Hendry (Manchester) emphasised the major discussion points of the Symposium. There was a general consensus on the need to improve and develop the available assays. The importance of obtaining a true indication of assay variability was stressed, in particular from the aspect of multiple repeat determinations on single individuals (as opposed to multiple assay determinations). There was a need to establish the most relevant technique and cell type that should be used for radiosensitivity testing, with respect to knowledge of the mechanisms of cell death and tissue response. A better definition of a normal range was considered to be extremely important. There was also a need for more experiments comparing cell types (e.g. tumour/normal; lymphocyte/fibroblast) within the same individual. Ways of increasing the magnitude of differences between individuals were promoted (e.g. using low dose rate). The importance of radiosensitivity measurements within a multivariate analysis in radiotherapy was stressed throughout. In particular combining radiosensitivity measurements with a measure of tumour proliferation was felt likely to increase the probability of predicting treatment response.
In a vote, all of those attending the meeting considered there was a future for radiosensitivity testing in general while around 75% considered there was a future within radiotherapy. Whether the techniques used at present will continue to be used remains to be seen. There was a general consensus that the area of work was exciting, that there was considerable scope for expansion and some hope that it might in the long term prove to be of value for routine evaluation of radiosensitivity.
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